Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of secukinumab in relapsing-remitting multiple sclerosis
2011-001629-25Phase 2Terminated
- Sponsor
- Novartis
- Start
- Oct 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of secukinumab in multiple sclerosis (MS), sponsored by Novartis. Primary endpoint: Long-term safety and tolerability of AIN457. Started Oct 2011; status: terminated.
02
Drugs
secukinumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2011-001629-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001629-25.